



5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 23-24, 2024 • Boston, MA

Saturday, March 23

7:00 - 8:00

BREAKFAST

8:00 - 8:15

INTRODUCTION AND WELCOME

8:15 - 9:35

CLINICAL UPDATES ON CAR T CELLS

CHAIRS: *Jesus San Miguel and Yi Lin*

8:15 - 8:25

Ide-cel: latest data and ongoing trials

Paula Rodriguez-Otero

8:25 - 8:35

Cilta-cel: latest data and ongoing trials

Jesus Berdeja

8:35 - 8:45

Real world outcomes with CAR T cells for MM

Surbhi Sidana

8:45 - 8:55

Update on GPRC5D CAR T cells

Omar Nadeem

8:55 - 9:35

Discussion

Session faculty + Nizar Bahlis

9:35 - 10:55

CLINICAL UPDATES ON BISPECIFIC ABS/TCE'S

CHAIRS: *Philippe Moreau and Hermann Einsele*

9:35 - 9:45

Teclistamab and Elranatamab: latest data and ongoing trials

Ajay Nooka

9:45 - 9:55

Talquetamab and Forimtamig: latest data and ongoing trials

Adam Sperling

9:55 - 10:05

The next bispecifics: Linvoseltamab, Alnuctamab, ABBV-383, Cevostamab

Hermann Einsele

10:05 - 10:15

Combining bispecifics with monoclonal Abs, IMiDs, and each other

Yael Cohen

10:15 - 10:55

Discussion

Session faculty + Emma Searle

10:55 - 11:25

BREAK

11:25 - 12:45

HOW TO USE T CELL-DIRECTED THERAPIES TODAY AND IN THE FUTURE

CHAIRS: *Kenneth Anderson and Marivi Mateos*

11:25 - 11:35	What is optimal duration of therapy for bispecifics?	Niels van de Donk
11:35 - 11:45	Sequencing CAR T cells and bispecifics for relapsed/refractory myeloma	Ajai Chari
11:45 - 11:55	How should we use T cell therapies in frontline and maintenance?	Luciano Costa
11:55 - 12:05	T cell therapies for smoldering myeloma	Irene Ghobrial
12:05 - 12:45	Discussion	Session faculty + Noopur Raje

12:45 - 1:45

LUNCH

1:45 - 3:15

NOVEL THERAPEUTIC APPROACHES AND TARGETS

CHAIRS: *Sonja Zweegman and Eric Smith*

1:45 - 1:55	Update on rapid manufacturing CAR T cell products	Shambavi Richard
1:55 - 2:05	Dual antigen-targeted CAR T cells and trispecific antibodies	Sham Mailankody
2:05 - 2:15	NK cell-based CAR and bispecific approaches	Binod Dhakal
2:15 - 2:25	Targeting CD229 for myeloma therapy	Tim Luetkens
2:25 - 2:35	Redirecting T cells against SLAMF7	Sophia Danhof
2:35 - 3:15	Discussion	Session faculty + Sundar Jagannath

3:15 - 3:35

BREAK

3:35 - 5:00

MANAGING TOXICITIES OF T CELL DIRECTED THERAPIES

CHAIR: *Pieter Sonneveld and Melissa Alsina*

3:35 - 3:45	Preventing infections after CAR T cell and bispecific Ab therapy	Noopur Raje
3:45 - 3:55	Immune effector cell-associated hematotoxicity	Kai Rejeski
3:55 - 4:05	Cardiac toxicity of CAR T cell therapy	Sarju Ganatra
4:05 - 4:15	Neurotoxicity associated with BCMA-targeted T cell therapies	Samir Parekh
4:15 - 5:00	Discussion	Session faculty + Adam Cohen

Sunday, March 24, 2023

7:00 - 8:00

BREAKFAST

8:00 - 8:05

WELCOME

8:05 - 8:35

PLENARY TALK

Stanley Riddell

Structure and function of novel bispecific chimeric T cell receptors

8:35 - 10:05

UNDERSTANDING RESISTANCE TO IMMUNE THERAPIES

CHAIRS: Mehmet Samur and Marta Chesi

8:35 - 8:45

Mechanisms of antigen escape after T cell-redirecting therapies

Paola Neri

8:45 - 8:55

Using multi-omics to identify biomarkers of response to CAR T cell therapy

Maximilian Merz

8:55 - 9:05

Spatial profiling to interrogate the microenvironment

Madhav Dhodapkar

9:05 - 9:15

Using circulating tumor DNA to predict response or resistance

Hitomi Hosoya

9:15 - 9:25

Preclinical models to predict immune evasion

Jose Martinez-Climent

9:25 - 10:05

Discussion

Session faculty + Adam Cohen

10:05 - 10:30

BREAK

10:30 - 12:00

NOVEL APPROACHES TO IMPROVE T CELL THERAPIES

CHAIRS: Ivan Borrello and Samir Parekh

10:30 - 10:40

Modulation of the microenvironment

Marc Raab

10:40 - 10:50

Disrupting Blimp-1 to enhance CAR T cell therapy

Carlos Fernandez de Larrea

10:50 - 11:00

Novel targets and technologies for CAR-T in MM

Michael Hudecek

11:00 - 11:10

In situ PEGylation to reduce CAR T cell-associated toxicities

Michael Mitchell

11:10 - 11:20

Clutch control: changing speed and direction of CAR T cell therapies

Carl Novina

11:20 - 12:00

Discussion

Session faculty + Nizar Bahlis

12:00 - 1:00

LUNCH

1:00 - 2:00

CURRENT QUESTIONS IN IMMUNE EFFECTOR CELL THERAPIES FOR MM

CHAIRS: Shaji Kumar and Kwee Yong

1:00 - 1:10

Should we profile T cell fitness prior to T cell-redirecting therapy?

Bruno Paiva

1:10-1:20

Should we profile antigen expression/mutation status prior to T cell-redirecting therapy?

Leo Rasche

1:20-1:30

Can vaccines or novel checkpoint inhibitors enhance response to CARTs or BsAbs?

David Avigan

1:30-2:00

Discussion

Session faculty + Marc Raab

2:00 - 3:15	WORKSHOP ON EXPANDING ACCESS TO T CELL THERAPIES	
	CHAIRS: <i>Nikhil Munshi and Amrita Krishnan</i>	
2:00-2:10	Improving clinical trial enrollment of underrepresented populations	Monique Hartley-Brown
2:10-2:20	Improving real-world access to T cell therapies in the US	Ben Derman
2:20-2:30	Challenges associated with T cell therapies in South America	Vania Hungria
2:30-3:15	Discussion	Session faculty + Kenneth Anderson, Sundar Jagannath, Philippe Moreau

3:15-3:30 **CONCLUSION AND WRAP-UP**

Thank you to our sponsors

TITANIUM



Johnson & Johnson

sanofi

PLATINUM



GOLD



SILVER

